Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female subjects who are ≥18 years of age on the day of signing informed consent.~* Diagnosis of moderate to severe ankylosing spondylitis with documented evidence of fulfilling the Modified New York (NY) criteria~* Have active ankylosing spondylitis with a BASDAI ≥4 (numeric rating scale \[NRS\] 0-10) and spinal pain ≥4 (0-10 NRS) (based on BASDAI question 2, see protocol) at screening and baseline.~* Have had a documented inadequate response to NSAIDs including cyclooxygenase-2 (COX-2) inhibitors.~* If using cDMARD therapy, stable dose for at lead 4 weeks prior to Baseline.~* If using non-drug therapies (including physical therapies), these should be kept stable during screening.~* Male and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use highly effective methods of contraception as described in the protocol.~Key Exclusion Criteria:~* Use of JAK inhibitors, investigational or approved, at any time, including filgotinib;~* Prior use of more than one TNF inhibitor, at any time.~* Use of oral steroids at a dose \>10 mg/day of prednisone or prednisone equivalent or at a dose that hasn't been stable for at least 4 weeks prior to baseline;~* Any therapy by intra-articular injections (e.g. corticosteroid, hyaluronate) within 4 weeks prior to screening;~* Use of more than 1 NSAID or COX-2 inhibitor.~* Contraindication to MRI.~* History of known or suspected complete ankylosis of the spine.~* Presence of very poor functional status or unable to perform self-care.~* Have undergone surgical treatment for ankylosing spondylitis within the last 12 weeks prior to screening.~* Administration of a live or attenuated vaccine within 12 weeks prior to baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- oral filgotinib tablets (Type: EXPERIMENTAL): None
- placebo tablets (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).